|
ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
Email:
sacfs@sacfs.asn.au
Mailing address:
GPO Box 383,
Adelaide,
South Australia 5001
Office:
266 Port Road,
Hindmarsh,
South Australia 5007
Ph: (08) 8346 3237
('834 MECFS')
Office Hours:
Wednesdays, 10am-3pm
Support Line:
(Mondays and Thursdays,
10am-3pm)
Ph: (08) 8346 3237
SA country callers:
Ph: 1300 128 339
(local call)
FIBROMYALGIA HELP: Contact Fibromyalgia SA at the Arthritis Foundation of SA 118 Richmond Road, Marleston 5033 Ph: (08) 8379 5711 |
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
Disclaimer
ME/CFS Australia (SA) Inc aims to keep members informed of the various research projects, diets, medications, therapies etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
| Become a Member | |||
|
University of Utah recruiting for pregabalin biomarker study
Friday 20 July 2012
U of Utah Recruiting Fibromyalgia & FM/CFS Patients for Pregabalin Biomarker Study
Why does Lyrica® (generic name pregabalin) help some FM patients and not others?
The Department of Anesthesiology at the University of Utah, Salt Lake City, announced July 10 that it is seeking participants for a study to investigate Lyrica’s “effects on blood biomarkers” in patients with fibromyalgia or FM & chronic fatigue syndrome (ME/CFS).
Lyrica (pregabalin) is a prescription drug marketed by Pfizer that gained FDA approval in 2007* for treatment of fibromyalgia.
Study Details
According to the July 10 blood biomarkers study announcement:
- Researchers hope to learn more about why Lyrica is effective for some patients and not for others.
- Volunteers with fibromyalgia (FMS) or chronic fatigue syndrome and FMS who are not currently using Lyrica are needed to participate in this IRB-approved trial.
- Eligible volunteers will receive Lyrica for five weeks and a placebo for five weeks, and will be compensated for their time.
- For more information, contact Andrea White (andrea.white@hsc.utah.edu)
___
* As Pfizer's Lyrica patents begin expiring, in October 2013, the $3.4 billion annual Lyrica market will be opening to ‘generic’ (generally lower price) versions of the drug, and as of July 5, the FDA approved marketing of a generic pregabalin product by Lupin Pharmaceuticals.
The above originally appeared here.
|
More Fibromyalgia News |
blog comments powered by Disqus
Previous Page |
